Replies to post #429530 on Anavex Life Sciences Corp (AVXL)

[kevindenver]

No company goes this quiet for no reason.

Unless S1R and muscarinic modulation proves out to be a failure, of which I don't think that's the case. I base that opinion on the growing body of S1R academic research and not from Anavex exclusively.

Heck a friend passed me this random academic S1R tidbit this afternoon:

The Neuroprotective Effect of Activation of Sigma-1 Receptor on Neural Injury by Optic Nerve Crush
https://pubmed.ncbi.nlm.nih.gov/37669061/

Of course it's jus a rat study, but it's all part of a larger pattern.

I think it will be in the $8B -$12B range

is fair, but that valuation will not be upfront, but instead be part of a Contingent Value Rights deal.

[nidan7500]

Very impressive, if true. looks to be only trials done in Australia and other planned locations WW, none noted as in USA. ? Surprise ....?? https://www.clinicaltrials.gov/search?term=anavex&limit=25&page=1

from Blarcasamine

I think we are very close to knowing a lot more. No company goes this quiet for no reason. Now rest assure that if there was material bad news the company must report it. But why would there be bad news. We hit all end points for every trial we ever did. Something big is happening, but what? I think buyout because a partnership should not be this long to complete and should not stop the PR's like they have. I think it will be in the $8B -$12B range

[mike_dotcom]

$7 stocks don't get buyout offers of $100.

[kund]

Every scam bio board has this theory...why would any one pay billion(s) for a drug whose efficacy is in doubt because of made up data.

[bas2020]

Good thought process, Blar... there are likely many discussions in the works...

My personal take is we are in negotiations which has made the company clam up as to what the strategy is. I think we are very close to knowing a lot more. No company goes this quiet for no reason. We hit all end points for every trial we ever ran. Something big is happening, but what?

I doubt Anavex is having buyout talks (yet). However, there's likely several partnership discussions happening with regard to worldwide commercialization. Though preliminary, things will move rather quickly once the NDAs have been submitted. Via Nondisclosure Agreements, such information is being shared with all prospective partners, because part of the approval process is identifying and establishing certified manufacturing and distribution plans.

RAs want to see that Anavex will be able to serve the market when approval is given.